Noa Wertheimer
Director, Scientific Strategy Emendo Biotherapeutics
Noa Wertheimer, PhD, Director of Scientific Strategy at Emendo Biotherapeutics, bridges science and business to advance genome editing innovation. She earned her PhD in Molecular Biology from Tel Aviv University and has been with Emendo for five years. Noa leads strategic development of the company’s OMNI nuclease platform—comprising hundreds of novel enzymes mined from metagenomes—enabling flexible, next-generation editing solutions. She also supports partnerships and the expansion of technologies including prime and epigenome editing to broaden therapeutic applications.
Seminars
Tuesday 29th September 2026
Expanding Genome Accessibility Beyond SP-Cas9 Limitations Using Diverse Nuclease Platforms to Target Non-NGG PAM Sequences
12:15 pm
- Addressing SP-Cas9 PAM sequence limitations that restrict targetability to only five percent of the human genome for conventional gene editing applications
- Leveraging diverse nuclease platforms recognizing alternative PAM sequences to expand genome accessibility and enable precise editing across previously inaccessible genomic regions
- Implementing next-generation CRISPR technologies including prime editors and base editors requiring PAM flexibility to achieve nucleotide-specific edits at desired genomic locations
